ClinicalTrials.gg
TerminatedNCT05141357HBI-8000Updated Dec 24, 2025Results posted

A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer

A Phase 2 interventional study of HBI-8000 in combination with pembrolizumab in Non Small Cell Lung Cancer, sponsored by HUYABIO International, LLC.. Terminated at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by HUYABIO International, LLC. · Phase 2, Interventional, and Treatment

Why this study was terminated
Slow Recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung — 29 open to participants now, 48 under way, 13 of them phase 3. pembrolizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
124th of 127
5 · median 65
Started
2022
with 8 others
Phase 2
65 of 127
20 open now
Registered
89th of 127
by date

Among the 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung, this one is the 124th largest by enrollment, is one of 9 that started in 2022, is one of 65 in phase 2, and was the 89th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

29 of the 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung are open now, in 10 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

A Phase 2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Pembrolizumab for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Read the detailed description

This Phase 2 study evaluates HBI-8000, a histone deacetylase inhibitor (HDACi) in combination with pembrolizumab for the treatment of patients with advanced or metastatic non-small cell lung cancer who possess programmed death ligand 1 (PD-L1) expression Tumor Proportion Score (TPS) of 1% or greater.

The Treatment Phase allowed for up to 24 months of treatment (cycles were 21 days), providing the subject did not experience disease progression or unacceptable toxicity.

03

Conditions studied

  • Non Small Cell Lung Cancer

Keywords

  • HBI-8000
  • Pembrolizumab
  • NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults at least 18 years of age.
  2. (ECOG) performance status ≤2.
  3. Histopathologically confirmed diagnosis of NSCLC expression TPS ≥1% as determined by an FDA-approved test.
  4. Have at least one measurable target lesion as defined by v.1.1.
  5. Have not received immune checkpoint inhibitor therapy or more than one regimen of chemotherapy for advanced or disease. Subjects who have previously received immune checkpoint inhibitor therapy in the or neoadjuvant setting may be allowed if disease progression occurred >6 months after the last dose and no immune related toxicities leading to treatment discontinuation were observed.
  6. Prior adjuvant or neoadjuvant systemic therapy with chemotherapy, EGFR or ALK mutation directed therapy must have been completed >4 weeks before Cycle 1 Day 1 (C1D1) dosing and recovered from all treatment related toxicity.
  7. Any prior palliative radiotherapy or minor surgery must be completed at least 2 weeks and 1 week respectively before C1D1 dosing and recovered from all treatment related toxicities.
  8. Adequate major organ functions at baseline as evidenced by laboratory findings within 14 days prior to C1D1 study drug administration as defined below:

    1. White blood cells (WBC) ≥3000/μL, neutrophils ≥1500/μL, ≥100×103/μL, ≥9.0 g/dL, independent of transfusion.
    2. Serum creatinine ≤1.5 mg/dL, normal electrolytes, phosphorus, and calcium.
    3. (AST) and alanine aminotransferase (ALT) ≤3 × (ULN), alkaline phosphatase ≤2.5 × ULN unless bone metastases present, ≤1.5 × ULN (unless known Gilbert's disease where it must be ≤3 × ULN) and serum albumin ≥3.0 g/dL.
    4. Thyroid stimulating hormone (TSH) within normal limits.
  9. ≥12 weeks.
  10. A negative serum pregnancy test at baseline for women of (WOCBP).
  11. Women of childbearing potential. (WOCBP), non-surgically sterile or premenopausal female capable of becoming pregnant and men (due to potential risk of drug exposure through the ejaculate) must agree to use an acceptable method of while enrolled on this study, and for a period of 5 months following the last dose of treatment. Acceptable methods of birth control in this trial include 2 highly effective methods of birth control (as determined by the Investigator; one of the methods must be a barrier technique) or abstinence.
  12. Have the ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria

  1. History of Grade ≥3 reactions to monoclonal antibodies.
  2. History of a cardiovascular illness including: corrected by heart rate using Fridericia's correction formula (QTcF) >450 ms in male or >470 ms in female, congenital long QT syndrome, congestive heart failure ( Grade III or IV) (Protocol Appendix 2); unstable angina or myocardial infarction within the previous 6 months; or symptomatic cardiac arrhythmia despite medical management.
  3. Uncontrolled hypertension, systolic blood pressure (SBP) >160 mmHg or diastolic blood pressure (DBP) >100 mmHg.
  4. Central nervous system or except when treatment for is completed >14 days prior to C1D1 and stable for ≥4 weeks on \<10 mg daily prednisone or equivalent.
  5. History of hemorrhagic diarrhea, inflammatory bowel disease, active uncontrolled peptic ulcer disease or bowel resection that affects absorption of orally administered drugs.
  6. Recurrent pleural effusion requiring repetitive palliative thoracentesis within 3 months prior to study entry, except for subjects with a pleurex port.
  7. Active, known, or suspected disease, or history of immune-mediated toxicity leading to treatment discontinuation, except for type I diabetes mellitus, hypothyroidism only requiring hormone replacement or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic therapy.
  8. Active pneumonitis, history of non-infectious pneumonitis that required treatment with , or history of interstitial lung disease.
  9. Active uncontrolled bacterial, viral, or fungal infection requiring systemic therapy.
  10. Known history of testing positive for (HIV), known acquired immunodeficiency syndrome (AIDS).
  11. Active (hepatitis B surface antigen [HBVsAg] positive), or (HCV antibody test or serum hepatitis C ribonucleic acid [RNA] positive).
  12. Received approved within 30 days of planned C1D1. Inactivated viral vaccines or vaccines based on subviral component are allowed; however intranasal influenza vaccines (e.g., Flu-Mist) are not allowed. COVID-19 vaccination should be administered >7 days before C1D1.
  13. Any condition requiring chronic systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other medications, or steroids use within 14 days of study drug administration. Inhaled or topical steroids are permitted.
  14. Use of other agent (drug not marketed for any indication) within 28 days or at least 5 half-lives (whichever is shorter) before study drug administration.
  15. Pregnant or breast-feeding women.
  16. Second unless in remission for 2 years; subjects with non-melanomatous skin cancer, carcinoma in situ of the cervix treated with curative intent, or curatively treated prostate cancer with prostate-specific antigen (PSA) \<2.0 ng/mL can be included.
  17. Underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity determination or adverse events.
  18. Unwilling or unable to comply with procedures required in this protocol.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    HBI-8000 in combination with pembrolizumab

    HBI-8000 - 30 mg/dose, orally twice a week; Pembrolizumab - 400 mg every 6 weeks or 200 mg every 3 weeks according to Prescribing Information and institutional practice

    Drug: HBI-8000 in combination with pembrolizumab

Interventions

  • DrugHBI-8000 in combination with pembrolizumab

    Drug pages: Tucidinostat · Pembrolizumab

    Participants will take 30 mg of HBI-8000 by mouth every 3-4 days on a twice weekly (BIW) schedule. Pembrolizumab will be administered at 400 mg IV every 6 weeks (Q6W) or 200 mg IV every 3 weeks (Q3W) according to Prescribing Information and institution's prescribing practice for pembrolizumab.

    Also known as: tucidinostat, Keytruda®, pembrolizumab

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of HBI-8000 When Administered in Combination With Standard Dose and Regimen of Pembrolizumab

    Number of participants experiencing treatment-emergent adverse events (TEAEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0

    Time frame: From the start of treatment until 30 days after the last dose of HBI-8000, up to approximately 13 months

07

Results

Posted Dec 24, 2025

Participant flow

This was a multicenter (9 sites in the US: hospital, regional medical, and research centers), open label, Phase 2 study of HBI 8000 in combination with an approved dose of pembrolizumab as a first line checkpoint inhibitor therapy for advanced or metastatic non-small cell lung cancer (NSCLC). Recruitment was from 15Feb 2022 to 01Sep2022. In December 2022, enrollment was suspended.

Participant flow — Overall Study
MilestoneHBI-8000 in Combination With Pembrolizumab
Started5
Completed0
Not completed5
Withdrew: Adverse event3
Withdrew: Lack of efficacy2

Outcome measures

PrimarySafety and Tolerability of HBI-8000 When Administered in Combination With Standard Dose and Regimen of Pembrolizumab

Number of participants experiencing treatment-emergent adverse events (TEAEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0

Time frame:
From the start of treatment until 30 days after the last dose of HBI-8000, up to approximately 13 months
Reported as:
Count of participants · Participants
Safety and Tolerability of HBI-8000 When Administered in Combination With Standard Dose and Regimen of Pembrolizumab
ParticipantsHBI-8000 in Combination With Pembrolizumab
Subjects experiencing TEAEs5
Subjects not experiencing TEAEs0

Adverse events

Collected over Up to approximately 13 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HBI-8000 in Combination With Pembrolizumab0/5 (0%)3/5 (60%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventHBI-8000 in Combination With Pembrolizumab
DiarrhoeaGastrointestinal disorders1/5
Gastrointestinal hemorrhageGastrointestinal disorders1/5
IleusGastrointestinal disorders1/5
COVID-19 pneumoniaInfections and infestations1/5
CellulitisInfections and infestations1/5
PneumoniaInfections and infestations1/5
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/5
HypoxiaRespiratory, thoracic and mediastinal disorders1/5
Pleural effusionRespiratory, thoracic and mediastinal disorders1/5
HypotensionVascular disorders1/5
Most frequent other events
Showing 10 of 81
Most frequent other events
EventHBI-8000 in Combination With Pembrolizumab
DiarrhoeaGastrointestinal disorders4/5
Decreased appetiteMetabolism and nutrition disorders4/5
AnaemiaBlood and lymphatic system disorders3/5
Iron deficiency anemiaBlood and lymphatic system disorders3/5
ThrombocytopeniaBlood and lymphatic system disorders3/5
NauseaGastrointestinal disorders3/5
Sinus tachycardiaCardiac disorders2/5
VomitingGastrointestinal disorders2/5
FatigueGeneral disorders2/5
Oedema peripheralGeneral disorders2/5

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)HBI-8000 in Combination With Pembrolizumab
<=18 years0
Between 18 and 65 years0
>=65 years5
Sex: Female, Male
Sex: Female, Male(Participants)HBI-8000 in Combination With Pembrolizumab
Female4
Male1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HBI-8000 in Combination With Pembrolizumab
Hispanic or Latino0
Not Hispanic or Latino4
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HBI-8000 in Combination With Pembrolizumab
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White4
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)HBI-8000 in Combination With Pembrolizumab
United States5
08

Study locations

7 sites
  • Western Regional Medical Center
    Goodyear, Arizona 85338, United States
  • CBCC Global Research, Inc at Comprehensive Blood and Cancer Center
    Bakersfield, California 93309, United States
  • Hematology Oncology Associates Of The Treasure Coast
    Port Saint Lucie, Florida 34952, United States
  • Southeastern Regional Medical Center
    Newnan, Georgia 30265, United States
  • Midewestern Regional Medical Center, LLC
    Zion, Illinois 60099, United States
  • Cotton O'Neil Clinical Research Center
    Topeka, Kansas 66606, United States
  • Frederick Health-JMSCI
    Frederick, Maryland 21702, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Apr 2023, 14 months.

Results were first posted in Dec 2025, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2021
First posted
Dec 2, 2021
StartActual
Feb 15, 2022
Primary completionActual
Apr 19, 2023
CompletionActual
Apr 19, 2023
Results first posted
Dec 24, 2025
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05141357
Lead sponsor
HUYABIO International, LLC.
Responsible party
Sponsor
First posted
Dec 2, 2021
Start date
Feb 15, 2022
Primary completion
Apr 19, 2023
Completion
Apr 19, 2023
Results posted
Dec 24, 2025
Last update
Dec 24, 2025

Study contacts

Gloria Lee, MD, PhD
study director · HUYABIO International, LLC.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tucidinostat · Pembrolizumab

Start the discussion